초록 ▼

A nutritional formula for PKU patients. The nutritional formula has, as a protein source, a mixture of caseino-glyco-macropeptide and complementary essential amino acids other than Phe to provide a balanced amino acid profile. Vitamins and minerals sufficient to meet daily requirements are also incl

A nutritional formula for PKU patients. The nutritional formula has, as a protein source, a mixture of caseino-glyco-macropeptide and complementary essential amino acids other than Phe to provide a balanced amino acid profile. Vitamins and minerals sufficient to meet daily requirements are also included. When used as a complete diet, the nutritional formula includes a carbohydrate source and a fat source. However the nutrutional formula may also be used as a protein supplement in which case the carbohydrate source and the fat source may be omitted. The nutritional formula has a pleasant taste.

대표청구항 ▼

A nutritional formula for PKU patients. The nutritional formula has, as a protein source, a mixture of caseino-glyco-macropeptide and complementary essential amino acids other than Phe to provide a balanced amino acid profile. Vitamins and minerals sufficient to meet daily requirements are also incl

A nutritional formula for PKU patients. The nutritional formula has, as a protein source, a mixture of caseino-glyco-macropeptide and complementary essential amino acids other than Phe to provide a balanced amino acid profile. Vitamins and minerals sufficient to meet daily requirements are also included. When used as a complete diet, the nutritional formula includes a carbohydrate source and a fat source. However the nutrutional formula may also be used as a protein supplement in which case the carbohydrate source and the fat source may be omitted. The nutritional formula has a pleasant taste. USA, 1993, 90, 11217-11221. Sell et al., "Effect of a Null Mutationof the Insulin-Like Growth Factor I Receptor Gene on Growth and Transformation of Mouse Embryo Fibroblasts", Mol. Cell. Biol., 1994, 14, 3604-3612. Valentinis et al., "The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen", Oncogene, 1994, 9, 825-831. Coppola et al., A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor. Resincoff et al., "Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor-1 (IGF-1) Receptor are Nontumorigenic and Induce Regression o Wild-Type Tumors", Cancer Res., 1994, 54, 2218-2222. Resincoff, M., et al., "Growth Inhibition of Human Melanoma Cells in Nude Mice by Antisense Strategies to the Type 1 Insulin-like Growth Factor Receptor", Cancer Res., 1994, 54, 4848-4850. Harrington et al., "c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines", EMBO J., 1994, 13, 3286-3295. Goldring and Goldring, "Cytokines and Cell Growth Control", Crit. Rev. Eukaryot. Gene Expr., 1991, 1, 301-326. Baserga and Rubin, "Cell Cycle and Growth Control", Crit. Rev. Eukaryot. Gene Expr., 1993, 3, 47-61. Pietrzkowski et al., "Constitutive Expression of Insulin-like Growth Factor 1 and Insulin-like Growth Factor 1 Receptro Abrogates All Requirements for Exogenous Growth Factors", Cell Growth & Diff, 1992, 3, 199-205. Pietrzkowski et al., "Roles of Insulinlike Growth Factor 1 (IGF-1) and the IGF-1 Receptor in Epidermal Growth Factor-Stimulated Growth of 3T3 Cells", Mol. Cell. Biol., 1992, 12, 3883-3889. Buttyan, R., et al., "Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death", Mol. Cell Biol., 1989, 9, 3473-3481. Kaufman, S.H., "Induction of Endonucleolytic DNA Cleavage in Human Acute Myelogenous Leukemia Cells by Etoposide, Camptothecin, and Other Cytotoxic Anticancer Drugs: A Cautionary Note", Cancer Res., 1989, 49, 5879-5878. Barry, M.A., et al., "Activation of Programmed Cell Death by Cisplatin, Other Anticancer Drugs, Toxins and Byperthermia", Biochem Pharmacol, 1990, 40, 2353-2362. Bursch, W., et al., "Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats", Carcinogenesis, 1990, 11, 847-853. Lange et al., "IL-4-and IL-5-Dependent Protective Immunity to Onchocerca Volvulus infectie Larvae in BALB/cBYJ mice", J. Immunol., 1994, 153, 205-211. Lanza et al., "Xenogeneic Humoral Response to Islets Transplated in Biohybrid Diffusion Chambers", Transplantation, 1994, 57, 1371-1375. Trojan et al., "Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA", Science, 1993, 259, 94-97. Martin et al., "Development of an in Vitro Assay for the Survival of Cells Suspended from BA1112 Rat Sarcomas", Eur. J. Cancer Clin. Oncol., 1983, 19, 791-797. Preston et al., "Regulation of Apoptosis by Low Serum in Cells of Different Stages of Neoplastic Progression", Cancer Res., 1994, 54, 4214-4223. Brown, "Gene Therapy `Oversold` By Researchers, Jounalists", Washington Post, Dec. 8, 1995, pp. 1 and A22. Conley, "Transplantation of nervous system tumors in diffusion chambers", J. Neurosurg., 1974, 41, 332-338. Kolata, "In the rush toward gene therapy, some see a high risk of failure", The New York Times, Jul. 25, 1995, p. C3. Marshall, "Gene Therapy's Growing Pains," Science, 1995, 269, 1050-1055. Miller, et al., "Gene Gransfer and Antisense Nucleic Acid Techniques," Parasitology Today, 1994, 10(3), 92-97. Tseng, et al., "Antisense oligonucleotide technology in the development of cancer therapeutics," Cancer Gene Thereapy, 1994, 1(1), 65-71. Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research," Pharm. Tech., 1994, 102, 104, 106, 108, 110-112, and 114. Ray et al., "Ca2+ antagonists inhibit DNA fragmentation and